Huntington Bancshares Inc
Change company Symbol lookup
Select an option...
HBAN Huntington Bancshares Inc
AICAF Air China Ltd
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
SHW Sherwin-Williams Co
SHV iShares Short Treasury Bond ETF
Go

Financials : Banks | Mid Cap Value
Company profile

Huntington Bancshares Incorporated (Huntington) is a bank holding company. Through its subsidiaries, including its bank subsidiary, The Huntington National Bank (the Bank), the Company provides commercial and consumer banking services, mortgage banking services, automobile financing, recreational vehicle and marine financing, equipment leasing, investment management, trust services, brokerage services, insurance programs, and other financial products and services. Its segments include Consumer and Business Banking, Commercial Banking, Commercial Real Estate and Vehicle Finance, Regional Banking and The Huntington Private Client Group, Home Lending and Treasury/Other. The Bank offers commercial and consumer loans. Its consumer loans include automobile, home equity, residential mortgage, and recreational vehicle (RV) and marine finance loans. It offers demand deposits-noninterest-bearing, demand deposits-interest-bearing, money market deposits, and savings and other domestic deposits.

Closing Price
$13.84
Day's Change
-0.67 (-4.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.37
Day's Low
13.74
Volume
(Heavy Day)
Volume:
31,658,091

10-day average volume:
14,300,301
31,658,091

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

8:02 am ET November 5, 2020 (Globe Newswire) Print

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community. HopeConnectLearn provides education and connection for patients and their caregivers across the spectrum of disease, from a new diagnosis to relapse or refractory experiences.

HopeConnectLearn includes a website and social media channels where patients and caregivers can find information about this rare disease and tools to help empower patients in conversations with their physician, as well as patient stories.

"A hairy cell leukemia diagnosis or relapse or refractory experience can be daunting for patients, and connection with others navigating similar challenges can provide needed comfort and strength," said Jennifer Butler, Executive Vice President and General Manager, Innate Pharma US, Inc. "HopeConnectLearn provides a community for patients to connect with and learn from each others' experience, no matter where they are in their journey."

Hairy cell leukemia is a rare blood cancer accounting for two to three percent of all cases of adult leukemias in the U.S., with approximately 1,000 new cases diagnosed each year. The disease affects more men than women, and occurs most commonly in middle-aged or older adults. Its name stems from the thin, hair-like projections found on the surface of abnormal white blood cells that indicate the disease.

This is often a slow growing, or indolent, form of cancer, and 90 percent of patients will have a normal life expectancy. About 40 percent of patients will relapse in 5-10 years following first treatment.

"When facing a rare disease like hairy cell leukemia, patients derive hope from hearing directly from other patients and learning about their experiences," said Anna Lambertson, Executive Director of the Hairy Cell Leukemia Foundation. "It is important for patients and caregivers across the spectrum of disease to know that they are not alone."

Join the HopeConnectLearn community online at www.hopeconnectlearn.com, on Twitter @HopeConnectLrn, Instagram @HopeConnectLearn and at www.Facebook.com/HopeConnectLearn.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code   FR0010331421
Ticker code Euronext: IPH Nasdaq: IPHA
LEI         9695002Y8420ZB8HJE29

For additional information, please contact:

Investors                   Media
Innate Pharma               Innate Pharma
Tel.: +33 (0)4 30 30 30 30  Tracy Rossin (Global/US)
investors@innate-pharma.com Tel.: +1 240 801 0076
                            Tracy.Rossin@innate-pharma.com

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company's business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

_________________________

Lopez-Rubio M, Garcia-Marco JA. Current and emerging treatment options for hairy cell leukemia. Onco Targets Ther. 2015;8:21247-2156.

Troussard X, Cornet E. Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2017; 92(12): 1382-1390.

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. doi:10.3322/caac.21357.

Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev. 2014;28(5):197-203. doi:10.1016/j.blre.2014.06.003.

https://ml.globenewswire.com/media/6fa6d804-b598-4693-b42f-0d6f7aa480ab/small/innatevertnoir-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.